Faced with an explosion in the complexity of genomic, imaging and clinical data, AI is rapidly becoming an indispensable tool for oncologists.

New insights into breast cancer immunology and genomics support further segmentation of patient subgroups and treatment approaches, says Prof. Sherene Loi 

Trastuzumab has transformed the prognosis for women with HER2+ breast cancer. On the occasion of the ESMO Breast Cancer Virtual Congress 2021, leading oncology experts recall with enthusiasm the pioneering work of researchers like José Baselga in this field and push for continuous research to investigate how to further improve the treatment of this cancer sub-type

At ELCC 2021, Prof. Fiona Blackhall sees hope for improving patients’ poor prognoses on the horizon  

With the growing use of real-world evidence (RWE) to support regulatory approvals of new anti-cancer medicines in Europe and the USA, can this type of research ensure greater inclusion of women, the elderly, diverse ethnic groups, those with rare cancers and other under-represented populations in oncology studies?

According to Prof. Urania Dafni, high quality real-world evidence can provide broader information and more generalisable conclusions to verify the clinical applicability of evidence from RCTs 

Promising results with cancer vaccines based on specific antigen mutations in individual tumours, and typically used in combination with checkpoint inhibitors, are fuelling an upsurge of interest in cancer vaccination for patients with established cancer, explains Prof. Pedro Romero. 

However, researchers’ concerns about missing opportunities to publish their real-world evidence-based papers in high-ranked scientific journals are justified to some extent due to lack of ‘best practices’ from publishers and suitable peer reviewers for these study designs

This year’s recipient of the TAT Honorary Award Prof. Ruth Plummer, retraces the most significant milestones of her career in early phase studies